|
1
|
Fang M, Nakazawa M, Antonarakis ES and Li
C: Efficacy of abiraterone and enzalutamide in pre- and
postdocetaxel castration-resistant prostate cancer: A trial-level
meta-analysis. Prostate Cancer. 2017:85608272017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katreddy RR, Bollu LR, Su F, Xian N,
Srivastava S, Thomas R, Dai Y and Wu B: Correction: Do
psychological harms result from being labelled with an unexpected
diagnosis of abdominal aortic aneurysm or prostate cancer through
screening? A systematic review. BMJ Open. 8:e017565corr12018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McClinch K, Avelar RA, Callejas D,
Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB,
Schlatzer D and Cooper M: Small molecule activators of protein
phosphatase 2A for the treatment of castration-resistant prostate
cancer. Cancer Res. 22:48–63. 2018.
|
|
4
|
Song XL, Huang B, Zhou BW, Wang C, Liao
ZW, Yu Y and Zhao SC: miR-1301-3p promotes prostate cancer stem
cell expansion by targeting SFRP1 and GSK3β. Biomed Pharmacother.
3:2185–2195. 2018.
|
|
5
|
Ma F, Ye H, He HH, Gerrin SJ, Chen S,
Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, et al: SOX9 drives
WNT pathway activation in prostate cancer. J Clin Invest.
126:1745–1758. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xie Y, Lu W, Liu S, Yang Q, Carver BS, Li
E, Wang Y, Fazli L, Gleave M and Chen Z: Crosstalk between nuclear
MET and SOX9/β-catenin correlates with castration-resistant
prostate cancer. Mol Endocrinol. 28:1629–1639. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin GQ, He HC, Han ZD, Liang YX, Yang SB,
Huang YQ, Zhou L, Fu H, Li JX, Jiang FN, et al: Combined
overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical
recurrence-free survival in patients with prostate cancer. Onco
Targets Ther. 7:137–146. 2014.PubMed/NCBI
|
|
8
|
Wang G, Lunardi A, Zhang J, Chen Z, Ala U,
Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, et
al: Zbtb7a suppresses prostate cancer through repression of a
Sox9-dependent pathway for cellular senescence bypass and tumor
invasion. Nat Genet. 45:739–746. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carotenuto M, de Antonellis P, Chiarolla
CM, Attanasio C, Damiani V, Boffa I, Aiese N, Pedone E, Accordi B,
Basso G, et al: A therapeutic approach to treat prostate cancer by
targeting Nm23-H1/h-Prune interaction. Naunyn Schmiedebergs Arch
Pharmacol. 388:257–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andolfo I, De Martino D, Liguori L,
Petrosino G, Troncone G, Tata N, Galasso A, Roma C, Chiancone F,
Zarrilli S, et al: Correlation of NM23-H1 cytoplasmic expression
with metastatic stage in human prostate cancer tissue. Naunyn
Schmiedebergs Arch Pharmacol. 384:489–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancian M and Renzulli JF II:
Nonmetastatic castration-resistant prostate cancer: A modern
perspective. Urology. 116:13–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alabed YZ: Prostate cancer lytic bone
metastases imaged with 18F-fluorocholine PET/CT. Clin Nucl Med.
43:220–221. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kabir A, Zendehdel R and Tayefeh-Rahimian
R: Dioxin exposure in the manufacture of pesticide production as a
risk factor for death from prostate cancer: A meta-analysis. Iran J
Public Health. 47:148–155. 2018.PubMed/NCBI
|
|
15
|
Alexis O and Worsley A: An integrative
review exploring black men of African and Caribbean backgrounds,
their fears of prostate cancer and their attitudes towards
screening. Health Educ Res. 1:325–339. 2018.
|
|
16
|
Wan YP, Xi M, He HC, Wan S, Hua W, Zen ZC,
Liu YL, Zhou YL, Mo RJ, Zhuo YJ, et al: Expression and clinical
significance of SOX9 in renal cell carcinoma, bladder cancer and
penile cancer. Oncol Res Treat. 40:15–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song W, Kwon GY, Kim JH, Lim JE, Jeon HG,
Il Seo S, Jeon SS, Choi HY, Jeong BC and Lee HM:
Immunohistochemical staining of ERG and SOX9 as potential
biomarkers of docetaxel response in patients with metastatic
castration-resistant prostate cancer. Oncotarget. 7:83735–83743.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su ZH and Li JC: Genetic instability of
gene nm23H1 in colon cancer of Chinese patient. Shi Yan Sheng Wu
Xue Bao. 36:325–329. 2003.(In Chinese). PubMed/NCBI
|
|
19
|
Esposito S, Russo MV, Airoldi I, Tupone
MG, Sorrentino C, Barbarito G, Di Meo S and Di Carlo E: SNAI2/Slug
gene is silenced in prostate cancer and regulates neuroendocrine
differentiation, metastasis-suppressor and pluripotency gene
expression. Oncotarget. 6:17121–17134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang CS, Shih MK, Chuang CH and Hu ML:
Lycopene inhibits cell migration and invasion and upregulates
Nm23-H1 in a highly invasive hepatocarcinoma, SK-Hep-1 cells. J
Nutr. 135:2119–2123. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YI, Park S, Jeoung DI and Lee H: Point
mutations affecting the oligomeric structure of Nm23-H1 abrogates
its inhibitory activity on colonization and invasion of prostate
cancer cells. Biochem Biophys Res Commun. 307:281–289. 2003.
View Article : Google Scholar : PubMed/NCBI
|
